Modality
Multispecific
MOA
IL-17i
Target
CFTR
Pathway
Ferroptosis
MS
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
~Mar 2022
→ ~Jun 2023
Phase 3
Sep 2023
→ Mar 2031
Phase 3Current
NCT05110090
1,436 pts·MS
2023-09→2031-03·Completed
1,436 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-275.0y awayPh3 Readout· MS
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Complet…
Catalysts
Ph3 Readout
2031-03-27 · 5.0y away
MS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05110090 | Phase 3 | MS | Completed | 1436 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Sovarelsin | BioMarin | Phase 2 | CFTR |